Poster Presentations Session IV
Poster Presentations Session IV Tuesday, May 22, 2018
POSTERS SET-UP: 3:15 PM - 3:30 PM
POSTERS DISPLAY HOURS: 3:30 PM - 7:30 PM
POSTER AUTHOR DISCUSSION: 6:30 PM - 7:30 PM
POSTERS DISMANTLE: 7:30 PM


Poster display locations are shown below the poster codes
CANCER - Clinical Outcomes Studies
PCN1
A1
GASTROINTESTINAL EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB AND NIVOLUMAB
Irwin D1, Davis BM1, Bell J2, Galaznik A2, Garcia-Ribas I2
1Truven Health Analytics, an IBM Company, Bethesda, MD, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

PCN2
A2
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) - INCIDENCE BY AGE AND SEX AMONG PATIENTS RECEIVING OXALIPLATIN
Binder G1, Saunders WB2
1Helsinn Therapeutics, Iselin, NJ, USA, 2IBM Watson Health - Explorys, Charlotte, NC, USA

PCN3
A3
REVIEWING ADVERSE DRUG EVENT REPORTING BETWEEN RANDOMIZED CLINICAL TRIAL DATA AND REAL WORLD POST MARKET DATA FOR SORAFENIB AND SUNITINIB
Grothen AE, Rivera DR
National Cancer Institute, Rockville, MD, USA

PCN4
A4
WITHDRAWN

PCN5
A5
COMPARISON OF STRUCTURED VERSUS ABSTRACTED COMORBIDITIES USING ONCOLOGY EHR DATA FROM CANCER PATIENTS IN THE FLATIRON HEALTH NETWORK
Parrinello CM, Seidl-Rathkopf KN, Bourla AB, Nussbaum NC, Carson KR, Abernethy AP
Flatiron Health, New York, NY, USA

PCN6
A6
ICD-CODED INFORMATION ON SITES OF METASTASIS IN ONCOLOGY REAL-WORLD DATA IS SPECIFIC BUT NOT SENSITIVE
Parrinello CM, Seidl-Rathkopf KN, Bennette CS, Bourla AB, Nussbaum NC, Carson KR, Abernethy AP
Flatiron Health, New York, NY, USA

PCN7
A7
IMPACT OF SKELETAL-RELATED EVENTS ON ANTI-TUMOR THERAPY PATTERN IN PATIENTS WITH BONE METASTASES FROM PROSTATE CANCER
Bhowmik D1, Shi N2, Manjelievskaia J2, Song X3, Vidito SI1, Intorcia M4
1Amgen Inc., Thousand Oaks, CA, USA, 2IBM Watson Health, Cambridge, MA, USA, 3IBM Watson Health, Ann Arbor, MI, USA, 4Amgen GmbH, Zug, Switzerland

PCN8
A8
PATTERNS OF TREATMENT AND RECURRENCE IN PATIENTS WITH NON-METASTATIC MELANOMA WHO UNDERWENT LYMPH NODE DISSECTION SURGERY
Ndife B1, Tarhini A2, Ionescu-Ittu R3, Manceur AM3, Jacques P3, Laliberté F3, Duh MS4, Nakasato A1, Ghate SR1
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Cleveland Clinic, Cleveland, OH, USA, 3Groupe d'analyse, Ltée, Montreal, QC, Canada, 4Analysis Group, Inc., Boston, MA, USA

PCN9
A9
CPX-351 FOR THE TREATMENT OF NEWLY DIAGNOSED, THERAPY-RELATED ACUTE MYELOID LEUKEMIA (TAML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC): AN ANALYSIS OF CLINICAL BENEFIT
Chung KC, Ryan RJ, Louie AC
Jazz Pharmaceuticals, Inc., Palo Alto, CA, USA

PCN10
A10
EFFICACY AND SAFETY OF EVEROLIMUS IN THE TREATMENT OF METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Hyderboini RK1, Thode R1, Malode M1, Pinigani V1, Nathani J1, Veeranki P1, Paladugu G1, Nadimpally J1, Kumar N1, Palakurthy P1, Vsn M1, Dang A2
1MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India, 2MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, MA, India

PCN11
A11
COMPARATIVE EFFICACY OF CONSOLIDATION THERAPY AFTER CHEMORADIATION THERAPY (CRT) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC): A NETWORK META-ANALYSIS
Husain F1, Harari O2, Fazeli MS1, Zhang Y3
1Doctor Evidence, Santa Monica, CA, USA, 2MTEK Sciences, Vancouver, BC, Canada, 3AstraZeneca, Gaithersburg, MD, USA

PCN12
A12
EFFICACY AND SAFETY OF PD-1/PDL-1 INHIBITORS IN THE MANAGEMENT OF PREVIOUSLY TREATED ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (RCTS)
Natarajan J, Verma J, Venkatesh C
Scoreboard Analytics Solutions, Chennai, India

PCN13
A13
SYSTEMATIC LITERATURE REVIEW OF TREATMENTS FOR PATIENTS WITH UNTREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)
Song J1, Huang M2, Kelkar SS3, Zhou Z4, Zhang Y2
1Analysis Group, Inc., Los Angeles, CA, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3Analysis Group, Inc., New York, NY, USA, 4Analysis Group, Inc., Boston, MA, USA

PCN14
A14
EFFICACY AND SAFETY OF ENZALUTAMIDE IN METASTATIC PROSTATE CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Rashid M1, Shamshavali K1, Vsn M1, Hyderboini RK1, Thode R1, Namare S1, Belekar V1, Chakrawarthy M1, Dang A2
1MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, India, 2MarksMan Healthcare Solutions LLP, Health Economics and Outcomes Research (HEOR) and RWE (Real World Evidence), Navi Mumbai, MA, India

PCN15
A15
THE EFFICACY AND SAFETY OF NIVOLUMAB IMMUNOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
Gadi HR, Shukla M, Gollala mK, Thatavarti R
Excelra Knowledge Solutions, Hyderabad, India

PCN16
A16
APPROACHES FOR ESTIMATING THE COMPARATIVE EFFICACY OF TREATMENTS FOR PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) WITHIN CONNECTED AND DISCONNECTED NETWORKS OF EVIDENCE
Cope S1, Keeping ST1, Barazandegan M1, Ayers D1, Jansen JP2, Penrod JR3, Korytowsky B3, Juarez Garcia A3, Yuan Y3
1Precision Xtract, Vancouver, BC, Canada, 2Precision Xtract, Oakland, CA, USA, 3Bristol-Myers Squibb, Princeton, NJ, USA

PCN17
A17
CABOZANTINIB VERSUS STANDARD OF CARE IN THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA: A NETWORK META-ANALYSIS
Lister J1, Schmidt E1, Marteau F2, Vataire A2
1Analytica LASER, Lörrach, Germany, 2Ipsen Pharma SAS, Boulogne-Billancourt Cedex, France

PCN18
A18
COMPARATIVE EFFECTIVENESS OF TREATMENTS IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFR-MUTANT) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WHO FAILED ON PRIOR TARGETED THERAPIES: A SYSTEMATIC LITERATURE REVIEW (SLR)
Shor A1, Forsythe A1, Li S2, Galaznik A2
1Purple Squirrel Economics, New York, NY, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

PCN19
A19
EFFICACY AND SAFETY ANALYSIS OF RADIUM-223 IN PATIENTS WITH PROSTATE CANCER CASTRATION-RESISTANT AND BONE METASTASIS
Alfonso Quiñones PA1, Carrasquilla-Sotomayor M2, Alvis-Zakzuk NJ2, Romero Prada ME3, Alvis-Guzmán N2, Huerfano LM3
1Salutia, Bogotá, Colombia, 2ALZAK Group, Cartagena, Colombia, 3Fundación Salutia, Bogotá, Colombia

PCN20
A20
EMPHASIZING QUALITY OF LIFE IN TREATMENT RECOMMENDATIONS FOR NODE-POSITIVE STAGE III NON-SMALL CELL LUNG CANCER
Decker-Palmer M1, Delgado D1, Maloney JD2
1Thomas Jefferson University, Johnstown, PA, USA, 2University of Wisconsin, Madison, WI, USA

PCN21
WITHDRAWN

PCN22
A21
EVALUATING DIFFERENT INDIRECT TREATMENT COMPARISON APPROACHES: A CASE STUDY IN ACUTE MYELOID LEUKEMIA PATIENTS INELIGIBLE TO RECEIVE INTENSIVE CHEMOTHERAPY
Tremblay G1, Westley T1, Arondekar B2, Cappelleri J2, Chan G2, Forsythe A1, Briggs A3
1Purple Squirrel Economics, New York, NY, USA, 2Pfizer Inc, New York, NY, USA, 3University of Glasgow, Glasgow, UK

PCN23
A22
THE PROMISING ROLE OF PEMBROLIZUMAB IN THE MANAGEMENT OF PATIENTS WITH PD-L1-POSITIVE NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW
Gadi HR, Gollala mK, Kethireddy K, Ganta mR, Kankanampati N
Excelra Knowledge Solutions, Hyderabad, India

PCN24
A23
DURATION OF TREATMENT AND ECONOMIC BURDEN IN PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) NON–SMALL CELL LUNG CANCER (NSCLC) RECEIVING SECOND-LINE ALK INHIBITORS
Lin HM1, Hou P1, Huang H1, Desai A1, Jahanzeb M2
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2Sylvester Comprehensive Cancer Center University of Miami, Miami, FL, USA

PCN25
A24
THE EFFICACY OF SORAFENIB IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: A SYSTEMATIC REVIEW
Kethireddy K, Gadi HR, Shukla M, Rayavarapu jE, Voleti VB
Excelra Knowledge Solutions, Hyderabad, India

PCN26
A25
META-ANALYTICAL METHODS FOR ESTIMATING OUTCOMES FROM OVERALL RESPONSE RATE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
Wang L1, Lam H2, Wu J1, Shou Y1, Galaznik A1
1Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2ACADIA Pharmaceuticals Inc., San Diego, CA, USA

PCN27
A26
THE COST-EFFECTIVENESS ANALYSIS OF RHTPO VERSUS IL-11 ON THE TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA PATIENTS IN CHINA
Li L1, Yang F2, Xuan J3
1Fudan University, Shanghai, China, 2Shanghai Centennial Scientific Ltd, Shanghai, China, 3Sun Yat-sen University, Guangzhou, China

PCN28
A27
SAFETY AND EFFICACY OF NIMOTUZUMAB IN COMBINATION WITH RADIOTHERAPY IN GLIOBLASTOMA PATIENTS; SYSTEMMATIC REVIEW OF CLINICAL TRIALS
Gadi HR, Ganta mR, Gurram H, Rayavarapu jE
Excelra Knowledge Solutions, Hyderabad, India

PCN29
A28
SYSTEMATIC REVIEW OF POLY (ADP-RIBOSE) POLYMERASE INHIBITORS FOR TREATMENT OF OVARIAN CANCER
Menges B, Deitelzweig C, Lin J, Lingohr-Smith M, Lin G
Novosys Health, Green Brook, NJ, USA

PCN30
A29
COMPARATIVE EFFECTIVENESS ANALYSIS USING REAL WORLD EVIDENCE (RWE) AND APPLYING A CAUSAL MARGINAL STRUCTURAL MODEL: THE CASE OF SECOND-LINE TREATMENT IN PATIENTS WITH OVARIAN CANCER
Siebert U1, Kuehne F2, Arvandi M2, Hess LM3, Faries DE3, Beyrer J3, Matteucci Gothe R2, Gothe H2, Stojkov I2, Rochau U2, Oberaigner W2, Zeimet AG4, Marth C4
1UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria. Department of Health Policy and Management, Harvard T.H. Chan School of Public Health. Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA, 2Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, Hall i.T., Austria, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Medical University Innsbruck, Innsbruck, Austria

PCN31
WITHDRAWN

PCN32
A30
COMPARISON OF VIDEO-ASSISTED THORACIC SURGERY SEGMENTECTOMY (VATS-S) VERSUS VIDEO-ASSISTED THORACIC SURGERY LOBECTOMY (VATS-L) FOR STAGE I NON-SMALL CELL LUNG CANCER (NSCLC-I) IN CHINESE PATIENTS: A SYSTEMIC REVIEW AND META-ANALYSIS
Yin C1, Zhao M2, Roy S3, Metz L1
1Johnson & Johnson Medical Asia Pacific, Singapore, Singapore, 2China Pharmaceutical University, NanJing, China, 3Ethicon Inc, Somerville, NJ, USA

PCN33
A31
A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF PANITUMUMAB WITH CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER (MCRC) WITH LEFT-SIDED TUMORS
Zhou A1, Cameron C1, Mak D2
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Amgen Canada Inc., Mississauga, ON, Canada

PCN34
A32
EFFECTIVENESS OF PRIMARY TREATMENT FOR ELDERLY THAN 75 YEARS WITH PROSTATE CANCER: KOREAN NATIONAL HEALTH INSURANCE DATABASE
Park E, Shim J, Kang M, Choi I, Park J, Kang S, Yang J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, Korea, Republic of (South)

PCN35
WITHDRAWN

PCN36
A33
MEDI-APEX: A RETROSPECTIVE NON-INTERVENTIONAL STUDY OF PD-L1 PREVALENCE AND CLINICAL OUTCOMES FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN ASIA-PACIFIC”
Klein AB1, Suzuki H2, Ebi N3, Kim S4, Li Z5, Berton A6, Shire N1, Dalvi T1, Tajar A7, Lecomte C8
1AstraZeneca, Gaithersburg, MD, USA, 2Fukushima Medical University Hospital, Fukushima, Japan, 3Iizuka Hospital, Fukuoka, Japan, 4University of Ulsan College of Medicine, Seoul, Korea, Republic of (South), 5Sun Yat-Sen University, Guangzhou, China, 6AstraZeneca, Mölndal, Sweden, 7IQVIA, Reading, UK, 8QuintilesIMS, Paris, France

PCN37
A34
WITHDRAWN

PCN38
A35
LONG-TERM EPIDEMIOLOGICAL IMPACT OF PERTUZUMAB+TRASTUZMAB ON METASTATIC BREAST CANCER INCIDENCE IN CANADA
Williamson M1, Tomar A2, Tournier C3, Reydet E4, Gururaj K5, Coombes M4
1Genentech, South San Francisco, CA, USA, 2ZS Associates India Pvt. Ltd., Gurgaon, India, 3F.Hoffmann-La Roche AG, Basel, Switzerland, 4Hoffmann-La Roche Ltd., Mississauga, ON, Canada, 5ZS Associates International, Inc., Frankfurt, Germany

PCN39
A36
PATTERNS OF POST-DIAGNOSIS DEPRESSION AMONG LATE-STAGE CANCER PATIENTS: DO RACIAL/ETHNIC AND GENDER DISPARITIES EXIST?
Huo J, Hong Y, Xiao H, Wilkie DJ
University of Florida, Gainesville, FL, USA

PCN40
A37
EPIDEMIOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) FOR ADVANCED CERVICAL CANCER: A TARGETED LITERATURE REVIEW
Shao C1, Siddiqui MK2, Takyar J2, Zhou W1, Sen S1
1Merck & Co., North Wales, PA, USA, 2PAREXEL International, Chandigarh, India

PCN41
A38
THE PREVALENCE AND PREDICTORS OF CONCOMITANT USE OF TYROSINE KINASE INHIBITORS AND PROTON PUMP INHIBITORS IN OLDER ADULTS WITH CANCER: AN OBSERVATIONAL STUDY USING SEER-MEDICARE DATA
Sharma M1, Holmes HM1, Mehta HB2, Aparasu RR3, Chen H3, Johnson ML3
1The University of Texas Health Science Center, Houston, TX, USA, 2University of Texas Medical Branch, Galveston, TX, USA, 3College of Pharmacy, University of Houston, Houston, TX, USA

PCN42
A39
USE OF ANTI-DIABETIC MEDICATION IS NOT ASSOCIATED WITH CANCER RISK IN CHINESE PATIENTS WITH TYPE 2 DIABETES
He X1, Shi L2, Wu J1
1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China, 2Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA

PCN43
A40
METFORMIN USE AND THE RISK OF BREAST, OVARIAN, ENDOMETRIAL, AND CERVICAL CANCERS IN ELDERLY FEMALES IN THE USA
Patel J1, LeMasters TJ2, Tan X1, Sambamoorthi U1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University, School of Pharmacy, Morgantown, WV, USA

PCN44
A41
TRENDS AND FACTORS ASSOCIATED WITH RESPIRATORY ALLERGY CONDITIONS AMONG U.S. PROSTATE CANCER PATIENTS IN 2007-2016
Huo N, Li C, Chou C, Garza KB, Qian J
Auburn University Harrison School of Pharmacy, Auburn, AL, USA

PCN45
A42
POSTOPERATIVE COMPLICATION RATE OF THREE DIFFERENT SURGERIES IN THE TREATMENT OF LUNG CANCER IN CHINESE PATIENTS: LITERATURE REVIEW AND SINGLE-ARM META-ANALYSIS
Yin C1, Zhao M2, Roy S3, Metz L1
1Johnson & Johnson Medical Asia Pacific, Singapore, Singapore, 2China Pharmaceutical University, NanJing, China, 3Ethicon Inc, Somerville, NJ, USA

PCN46
A43
RETROSPECTIVE VALIDATION OF PREDICTED LONG-TERM SURVIVAL ESTIMATES FROM AN EARLY DATA CUT OF THE PHASE III CHECKMATE 025 STUDY IN ADVANCED RENAL CELL CARCINOMA
Johal S1, Smare C1, Malcolm B2, Doan J3
1PAREXEL Access Consulting, London, UK, 2Bristol-Myers Squibb, Uxbridge, UK, 3Bristol-Myers Squibb, Princeton, NJ, USA

PCN47
A44
CHARACTERIZING PATIENTS WITH STAGE III AND IV NON-SMALL CELL LUNG CANCER (NSCLC): GENERATING REAL WORLD EVIDENCE (RWE) FOR DECISION-MAKING IN BRAZIL
Okumura LM1, Fonseca EL1, Riveros BS2, Rosim MP3, Lucchetta RC2, Rol R4, Valverde DA4, Nita ME1
1MAPESolutions, São Paulo, Brazil, 2Universidade Federal do Paraná, Curitiba, Brazil, 3Universidade de São Paulo, São Paulo, Brazil, 4Techtrials, São Paulo, Brazil

PCN48
A45
REAL-LIFE AUTOLOGOUS STEM CELL TRANSPLANTATION AND OVERALL SURVIVAL RATES IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: AN ANALYSIS BASED ON A GERMAN CLAIMS DATASET
Mueller S1, Wilke T2, Maywald U3, Groth A2, Heidler T2, Heeg B4
1Ingress-Health HWM GmbH, Wismar, Germany, 2IPAM e.V., Wismar, Germany, 3AOK Plus - Die Gesundheitskasse für Sachsen und Thüringen, Dresden, Germany, 4Ingress Health, Rotterdam, The Netherlands

CANCER - Cost Studies
PCN49
A46
BUDGET IMPACT ANALYSIS FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN COSTA RICA
Torres Toala FG1, Solorzano J2, Baldi J2, Landaverde D3, González I3
1Makroscopio, Quito, Ecuador, 2AstraZeneca CAMCAR MAC, San José, Costa Rica, 3Caja Costarricense de Seguro Social, San Jose, Costa Rica

PCN50
A47
BUDGET IMPACT ANALYSIS OF OLAPARIB AS MAINTENANCE TREATMENT OF ADULT PATIENTS WITH PLATINUM-SENSITIVE RELAPSED BRCA-MUTATED (GERMLINE AND/OR SOMATIC) HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER WHO ARE IN RESPONSE (COMPLETE OR PARTIAL) TO BUDGET IMPACT ANALYSIS OF OLAPARIB (LYNPARZA®) AS MAINTENANCE TREATMENT OF ADULT PATIENTS WITH PLATINUM-SENSITIVE RELAPSED BRCA-MUTATED (GERMLINE AND/OR SOMATIC) HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER WHO ARE IN RESPONSE (COMPLETE OR PARTIAL) TO PLATINUM-BASED CHEMOTHERAPY IN MEXICO
Soria I, Carmona M, Naranjo M
AstraZeneca, Mexico, Mexico

PCN51
A48
BUDGET IMPACT OF NIRAPARIB AS MAINTENANCE TREATMENT FOR MEDICARE PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Neeser K, O'Neil WM, Stern L
Analytica Laser, New York, NY, USA

PCN52
A49
BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
Gay JG1, Schultz NM2, Braun S2
1T.I. Salud, Mexico, Mexico, 2Astellas Pharma Inc., Northbrook, IL, USA

PCN53
A50
ECONOMIC IMPACT OF LAPAROSCOPIC VS OPEN LOW ANTERIOR RESECTION FOR RECTAL CANCER SURGERY: A BUDGET IMPACT ANALYSIS
Lim S1, Chen BP1, Marsh W2, Ghosh W3, Entwistle J4, Goldstein LJ5
1Ethicon Inc, Somerville, NJ, USA, 2Costello Medical Consulting Ltd, Cambridge, UK, 3Costello Medical Singapore Pte Ltd, Singapore, Singapore, 4Johnson and Johnson, Leeds, UK, 5Johnson & Johnson, Markham, ON, Canada

PCN54
B1
BUDGET IMPACT ANALYSIS OF NIRAPARIB AND OLAPARUB AS MAINTENANCE THERAPY FOR PLATINUM SENSITIVE, RECURRENT OVARIAN CANCER IN THE US
Wu L, Zhong L
Texas A&M University, College Station, TX, USA

PCN55
B2
BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PERU
Torres Toala FG1, Solorzano J2, Baldi J2
1Makroscopio, Quito, Ecuador, 2AstraZeneca CAMCAR MAC, San José, Costa Rica

PCN56
B3
BUDGET IMPACT FOR OLAPARIB MAINTENANCE THERAPY FOR BRCA-MUTATED PLATINUM SENSITIVE RECURRENT OVARIAN CANCER IN PANAMA
Torres Toala FG1, Solorzano J2, Baldi J2, Castillo-Fernandez O3
1Makroscopio, Quito, Ecuador, 2AstraZeneca CAMCAR MAC, San José, Costa Rica, 3Instituto Oncologico Nacional, Panama, Panama

PCN57
B4
BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2− ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
Djambazov S1, Slavchev G1, Velchev M2, Vekov T3
1HTA Ltd., Sofia, Bulgaria, 2Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria, 3Medical University Pleven, Pleven, Bulgaria

PCN58
B5
BUDGET IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER IN SPECIALTIES HOSPITAL IN ECUADOR.
Irigoyen P1, Moreno A2, Gavilanes C3
1Hospital Fuerzas Armadas, Quito, Ecuador, 2Hospital Especialidades Eugenio Espejo, Quito, Ecuador, 3Health Technology Assessment, Quito, Ecuador

PCN59
B6
BUDGET IMPACT OF THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB TO U.S. HEALTH PLANS
Hansen RN1, Wallick CJ2, Sullivan SD1
1University of Washington, Seattle, WA, USA, 2Genentech, Inc., South San Francisco, CA, USA

PCN60
B7
USE OF PD-L1 BIOMARKER IN SECOND LINE THERAPY FOR NON-SMALL CELL LUNG CANCER: BUDGET IMPACT ANALYSIS FROM A PRIVATE PAYER PERSPECTIVE IN BRAZIL
Chabrol Haas L, Coutinho MB, Peixoto RB, Ranieri AS, Serra FB
MSD Brasil, São Paulo, Brazil

PCN61
B8
WITHDRAWN

PCN62
B9
THE CLINICAL AND ECONOMIC IMPACT OF DELAYS IN REIMBRSEMENT FOR SELECT NOVEL CANCER THERAPEUTICS IN CANADA, ITALY, AND AUSTRALIA
Leinwand B1, Johnsrud M2
1Avalere Health LLC, Washington, DC, USA, 2Avalere Health, Washington, DC, USA

PCN63
B10
CHEMOTHERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER: IS COST OF MEDICINE THE MOST IMPORTANT FINANCIAL BURDEN?
Gupta P, Nahata P, Malik PS, Sarangi SC, Gupta YK
AIIMS, Delhi, New Delhi, India

PCN64
B11
COSTS ASSOCIATED WITH FOLLICULAR LYMPHOMA AMONG MEDICARE BENEFICIARIES: AN INCREMENTAL COST ANALYSIS
Albarmawi H1, Nagarajan M2, Sun K1, Gandhi AB1, Yared JA3, Keating K4, Valderrama A5, Appukkuttan S4, Yaldo A4, Babajanyan S4, Gharibo M4, Onukwugha E1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 3University of Maryland, Greenebaum Cancer Center, Baltimore, MD, USA, 4Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA, 5Bayer US (Affiliation at the time that the study was conducted), Whippany, NJ, USA

PCN65
B12
HOSPITAL LENGHT OF STAY AND COSTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN66
B13
BURDEN OF HOSPITALIZATION IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015 USING ICD-9 AND ICD-10 DIAGNOSES
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN67
B14
TREATMENT PATTERNS AND ECONOMIC BURDEN OF CHINESE METASTATIC COLORECTAL CANCER PATIENTS: A RETROSPECTIVE STUDY OF ELECTRONIC MEDICAL RECORDS FROM URBAN CHINA
Shen L1, Ying X2, Li Q3, Wang W4, Zhu L5, Zhao Q6, Nie Y6, Zhu B7, Ma D8, Lin X9, Cai X10, Fang W11, Peng C12, Chen Y12, Fang H13, Li H12, Wang N12, Xu R14
1Beijing Cancer Hospital, Beijing, China, 2Fudan University, Shanghai, China, 3Shanghai General Hospital, Shanghai, China, 4The First People's Hospital of Foshan, Foshan, China, 5Jiangsu Province Hospital, Nanjing, China, 6Xijing Hospital, Fourth Military Medical University, Xi'an, China, 7Xinqiao Hospital, Third Military Medical University, Chongqing, China, 8Guangdong General Hospital, Guangzhou, China, 9Fujian Medical University Union Hospital, Fuzhou, China, 10Sichuan Cancer Hospital and Institute, Chengdu, China, 11The First Hospital of Zhejiang Province, Hangzhou, China, 12Eli Lilly and Company China Affiliate, Shanghai, China, 13IQVIA, Shanghai, China, 14Sun Yat-sen University Cancer Center, Guangzhou, China

PCN68
B15
LENGTH OF STAY, HOSPITLIZATION COST, AND IN-HOSPITAL MORTALITY ASSOCIATED WITH TUMOR LYSIS SYNDROME AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Aroke H, Cirincione A, Kogut S
University of Rhode Island, Kingston, RI, USA

PCN69
B16
TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH CHRONIC LYMPHOID LEUKEMIA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN70
B17
ONCOLOGY COMBINATION PRICING: IMPACT OF PRODUCT CHARACTERISTICS AND UNMET NEED
Madhavan P, Infante K, Harris B, Nash C
GfK, New York, NY, USA

PCN71
B18
ONCOLOGY COMBINATION PRICING: IMPACT OF NUMBER OF COMPETITORS AND OWNERSHIP DYNAMICS
Madhavan P, Infante K, Harris B, Nash C
GfK, New York, NY, USA

PCN72
B19
EVALUATING THE COST-EFFECTIVENESS OF NOVEL HEALTHCARE INTERVENTIONS: PROSPECTIVE ASSESSMENT OF T-CELL IMMUNOTHERAPY FOR ACUTE MYELOID LEUKEMIA
Razavilar N1, Wallner K1, Lachance S2, Delisle JS2, McCabe C1
1University of Alberta, Edmonton, AB, Canada, 2University of Montreal, Montreal, QC, Canada

PCN73
B20
ECONOMIC OUTCOMES OF MEDICARE REIMBURSEMENT POLICY CHANGE ON ERYTHROPOIESIS-STIMULATING AGENTS IN CANCER PATIENTS
Li MS1, Schulz RM2, Lu KZ2
1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of South Carolina, Columbia, SC, USA

PCN74
B21
COST TREATMENT COMPARISON OF ABIRATERONE ACETATE PLUS PREDNISONE IN THE PRE-CHEMOTHERAPY SETTING FOLLOWED BY ENZALUTAMIDE IN THE POST-CHEMOTHERAPY SETTING VERSUS THE OPPOSITE TREATMENT SEQUENCE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH NON-VISCERAL METASTASES IN PERU
De La Cruz-Vargas J1, Chavez-Villanueva N2, Guerrero E3, Aguirre A3, Ojeda-Botteri G4
1Universidad Ricardo Palma, Lima, Peru, 2Private Consultant, Lima, Peru, 3Janssen Cilag SA, Bogota, Colombia, 4Janssen, Lima, Peru

PCN75
B22
COSTS AND HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH HOSPITAL ADMISSIONS OF PROSTATE CANCER PATIENTS WITH OR WITHOUT METASTASIS
Valderrama A1, Tangirala K2, Appukkuttan S2, Simmons S2
1Bayer US (Affiliation at the time that the study was conducted), Whippany, NJ, USA, 2Bayer US, Whippany, NJ, USA

PCN76
B23
ASSESSING THE ECONOMIC BURDEN OF PROSTATE CANCER IN UGANDA
Seninde IK, Knoll B
Health Outcomes Measures and Analysis Lab (U) Ltd, Kampala, Uganda

PCN77
B24
REAL-WORLD OUT-OF-POCKET EXPENSES (OPE) AMONG ADVANCED (STAGE IIIB/C AND IV) BREAST CANCER (ABC) PATIENTS UNDERGOING TREATMENT IN THE UNITED STATES (US)
Byrne KS, Bailey A, Rider A
Adelphi Real World, Bollington, UK

PCN78
B25
PROSTATE CANCER COSTS IN COLOMBIA: A TOP-DOWN APPROACH
Gomez de la Rosa F1, Carrasquilla-Sotomayor M1, Alvis-Zakzuk NJ1, Acero Acero G2, Alfonso Quiñones PA2, Romero Prada ME2, Alvis-Guzmán N1
1ALZAK Group, Cartagena, Colombia, 2Fundación Salutia, Bogotá, Colombia

PCN79
B26
COSTS OF HODGKIN AND NON-HODGKIN LYMPHOMA IN FRANCE: RESULTS ON THE BASIS OF THE FRENCH NATIONAL HEALTH INSURANCE DATABASE
Mounie M1, Costa N2, Conte C2, Despas F2, Lapeyre Mestre M2, Laurent G3, SAvy N4, Molinier L2
1University Hospital of Toulouse, Toulouse, France, 2Centre Hospitalier Universitaire, Toulouse, France, 3Institut Universitaire du Cancer, Toulouse, France, 4Institut Mathématiques de Toulouse, Toulouse, France

PCN80
B27
WHAT ARE THE REAL INDIRECT COSTS ASSOCIATED WITH MULTIPLE MYELOMA: MODEL PATIENT ANALYSIS FROM SLOVAK REPUBLIC.
Babela R1, Rafayova M2, Hurna J3
1Institute for Healthcare Disciplines, BRATISLAVA, Slovakia, 2ROCON s.r.o. (CEE Consultancy Company), MALACKY, Slovakia, 3Janssen (J&J Company), BRATISLAVA, Slovakia

PCN81
B28
THE IMPACT OF POST-DIAGNOSIS DEPRESSION ON SURVIVAL AND HEALTHCARE COSTS FOR PATIENTS DIAGNOSED WITH LATE-STAGE CANCER IN THE UNITED STATES
Huo J, Hong Y, Xiao H, Wilkie DJ
University of Florida, Gainesville, FL, USA

PCN82
B29
ESTIMATION OF TOTAL BURDEN OF HEAD AND NECK CANCER IN BRAZIL – AN ECONOMIC AND CLINICAL APPROACH
Rosim MP1, Sarti FM1, Riveros B2, Pedro GO3, Lucchetta RC2, Okumura LM3, Nita ME3, Massaoka MH4, Matsuo AL4, Guerra RL5, Santos M6, Stefani S7
1University of Sao Paulo, sao paulo, Brazil, 2Federal University of Parana, Curitiba, Brazil, 3MAPESolutions, São Paulo, Brazil, 4AstraZeneca, Cotia, Brazil, 5National Institute of Cancer, Rio de Janeiro, Brazil, 6Brasilia University, Brasilia, Brazil, 7Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil

PCN83
B30
SOCIAL AND ECONOMIC IMPACT OF PATIENTS WITH METASTATIC BREAST CANCER IN BRAZIL
Alexandre RF, Santana CF, Squiassi HB
Pfizer, São Paulo, Brazil

PCN84
B31
ESTIMATION OF TOTAL BURDEN OF BLADDER CANCER IN BRAZIL – AN ECONOMIC AND CLINICAL APPROACH
Rosim MP1, Sarti FM1, Riveros B2, Pedro GO3, Lucchetta RC2, Okumura LM3, Nita ME3, Massaoka MH4, Matsuo AL4, Guerra RL5, Santos M6, Stefani S7, Fay AP8
1University of Sao Paulo, sao paulo, Brazil, 2Federal University of Parana, Curitiba, Brazil, 3MAPESolutions, São Paulo, Brazil, 4AstraZeneca, Cotia, Brazil, 5National Institute of Cancer, Rio de Janeiro, Brazil, 6Brasilia University, Brasilia, Brazil, 7Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil, 8PUCRS - School of Medicine, Porto Alegre, Brazil

PCN85
B32
COST-OF-ILLNESS AND TREATMENT PATTERNS OF GYNECOLOGIC CANCER IN THE UNITED STATES: AN EMPIRICAL ANALYSIS BASED ON MEPS DATABASE 2007-2014
Yue X, Hincapie A, Pruemer J, Guo JJ
University of Cincinnati, Cincinnati, OH, USA

PCN86
B33
SYSTEMATIC REVIEW OF THE DIRECT COST OF LUNG CANCER IN CHINA
JI Y1, Tang Z2, Fan L2, Xue D3
1Zhongshan Hospital, Fudan University, Shanghai, China, 2Bristol-Myers Squibb, Shanghai, China, 3Key Lab of Health Technology Assessment, School of Public Health, Fudan University, Shanghai, China

PCN87
B34
HOW MUCH OVARIAN CANCER REALLY COST FOR PATIENTS AND THEIR FAMILIES IN CHINA?
Zhang C1, Xu L2, Wang B2, HU C2
1Astrazeneca, Shanghai, China, 2Astrazeneca (China), Beijing, China

PCN88
B35
EVIDENCE MAP OF COST AND RESOURCE USE STUDIES IN ACUTE MYELOID LEUKAEMIA SINCE 1960
Furber AM
Crystallise, East Tilbury, UK

PCN89
B36
MEDICAL COST ANALYSIS OF OVARIAN CANCER PATIENTS IN CHINA
Chen B1, Fan CS1, Dong C2, Lu Y3
1Beijing Medical and Health Economic Research Association, Beijing, China, 2Chinese Academy of Labour and Social Security, Beijing, China, 3Shenyang Pharmaceutical University, School of Business Administration, China

PCN90
B37
TREATMENT PATTERNS AND COSTS ASSOCIATED WITH DIFFUSE LARGE B-CELL LYMPHOMA—A RETROSPECTIVE ANALYSIS OF CLAIMS
Garcia J1, Gitlin M2, Snyder S2, McMorrow D3, Bonafede MM3, Tkacz J3
1Juno Therapeutics, Seattle, WA, USA, 2BluePath Solutions, Los Angeles, CA, USA, 3Truven Health Analytics, an IBM Company, Cambridge, MA, USA

PCN91
B38
IMPACT OF DIFFUSE LARGE B-CELL LYMPHOMA ON COSTS OF CHRONIC CONDITIONS IN ELDERLY MEDICARE BENEFICIARIES
Garg R1, Sambamoorthi U2, Tan X2, Basu S3, Haggerty T2, Kelly K2
1Chicago State University, Chicago, IL, USA, 2West Virginia University, Morgantown, WV, USA, 3Geisinger - Hematology and Oncology, Wilkes-Barre, PA, USA

PCN92
B39
ECONOMIC BURDEN OF ADVANCED CERVICAL CANCER: A SYSTEMATIC LITERATURE REVIEW
Shao C1, Siddiqui MK2, Takyar J2, Zhou W1, Sen S1
1Merck & Co., North Wales, PA, USA, 2PAREXEL International, Chandigarh, India

PCN93
B40
TREATMENT PRACTICE PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HRU), AND COSTS IN NEWLY DIAGNOSED PATIENTS WITH THERAPY-RELATED ACUTE MYELOID LEUKEMIA (TAML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN A UNITED STATES (US) COMMERCIALLY INSURED POPULATION
Hagiwara M1, Sharma A1, Chung KC2, Delea TE1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Jazz Pharmaceuticals, Palo Alto, CA, USA

PCN94
B41
ESTIMATING THE LIFETIME COSTS IN ADULT PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
Garcia J1, Snyder S2, Gitlin M2
1Juno Therapeutics, Seattle, WA, USA, 2BluePath Solutions, Los Angeles, CA, USA

PCN95
B42
EVALUATION OF COST OF HOSPITALIZATIONS RELATED TO NAUSEA AND VOMITING AMONG CANCER PATIENTS
Roeland E1, Binder G2
1University of California San Diego Moores Cancer Center, La Jolla, CA, USA, 2Helsinn Therapeutics, Iselin, NJ, USA

PCN96
B43
ECONOMIC BURDEN AND TREATMENT PATTERNS FOR PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA IN THE UNITED STATES
Galaznik A1, Asche CV2, Ren J2
1Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 2University of Illinois College of Medicine at Peoria, Peoria, IL, USA

PCN97
B44
DIRECT COSTS ASSOCIATED WITH MULTIPLE MYELOMA MODEL PATIENT IN 2017 FROM SINGLE EU JURISDICTION.
Babela R1, Rafayova M2, Hurna J3
1Institute for Healthcare Disciplines, BRATISLAVA, Slovakia, 2ROCON s.r.o. (CEE Consultancy Company), MALACKY, Slovakia, 3Janssen (J&J Company), BRATISLAVA, Slovakia

PCN98
B45
COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS RELATED TO PLEURAL EFFUSION (PE) BETWEEN PATIENTS NEWLY DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH DASATINIB OR NILOTINIB AS FIRST-LINE THERAPY IN THE UNITED STATES
Seiter K1, Latremouille-Viau D2, Guerin A2, Ndife B3, Habucky K3, Joseph GJ3, Pivneva I2, Gagnon-Sanschagrin P2, Tang DH3
1New York Medical College and Westchester Medical Center, Valhalla, NY, USA, 2Analysis Group, Inc., Montreal, QC, Canada, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN99
B46
COST OF CARE FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN US COMMERCIALLY INSURED AND MEDICARE SUPPLEMENT PLANS
Wu B1, Li S2, Tunceli O1, Pericone C1, Ding Z1, Behl A2, Mangla K3, Dawson N4
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Janssen Scientific Affairs, LLC, Horsham, PA, USA, 3Mu Sigma Business Solutions, Bengaluru, India, 4Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC, USA

PCN100
C1
TOTAL COSTS DISTRIBUTION FOR MULTIPLE MYELOMA IN SINGLE UPPER MIDDLE INCOME COUNTRY: IS COST DATA DISTRIBUTION COMPARABLE WITH HIGH INCOME COUNTRIES?
Babela R1, Rafayova M2, Hurna J3
1Institute for Healthcare Disciplines, BRATISLAVA, Slovakia, 2ROCON s.r.o. (CEE Consultancy Company), MALACKY, Slovakia, 3Janssen (J&J Company), BRATISLAVA, Slovakia

PCN101
WITHDRAWN

PCN102
C2
POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
Schwartz NR1, Steuten L2, Babigumira JB1, Roth JA2
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

PCN103
C3
COST­-EFFECTIVENESS ANALYSIS OF MIDOSTAURIN (MIDO) WITH STANDARD OF CARE (SOC) FOR ACUTE MYELOID LEUKEMIA (AML) IN CANADA
Tremblay G1, Dolph M1, El Ouagari K2, Brandt P3, Forsythe A1
1Purple Squirrel Economics, New York, NY, USA, 2Novartis Pharmaceuticals Canada Limited, Dorval, QC, Canada, 3Novartis Pharmaceuticals, East Hanover, NJ, USA

PCN104
C4
A SYSTEMATIC LITERATURE REVIEW OF THE METHOLODIGCAL APPROACHES AND CONCLUSIONS FROM PUBLISHED COST-EFFECTIVENESS MODELS IN THE TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS
Garcia J1, Snyder S2, Gitlin M2
1Juno Therapeutics, Seattle, WA, USA, 2BluePath Solutions, Los Angeles, CA, USA

PCN105
C5
COST-EFFECTIVENESS OF CERITINIB IN PREVIOUSLY UNTREATED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE UNITED KINGDOM
Xie J1, Knoll S2, Slowley A3, Bensimon A4, Vieira J3, Chilcott J5, Paisley S5, Zhou Z6
1Analysis Group, Inc., New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Pharmaceuticals UK Limited, GB- Frimley/Camberley, Surrey, UK, 4Analysis Group, Inc., Boston, MA, USA, 5University of Sheffield, Sheffield, UK, 6Analysis Group, Inc., London, UK

PCN106
C6
COST-EFFECTIVENESS ANALYSIS OF DIFFERENT TREATMENT IN ADVANCED PROSTATE CANCER.
Alsahali S1, Alzarea AI2, Alsumali A3, Rittenhouse B3, Eguale T3
1Qassim University, Buridah, Saudi Arabia, 2Al-jouf University, Skaka, Saudi Arabia, 3MCPHS University, Boston, MA, USA

PCN107
C7
COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
Kim J, Hay JW
University of Southern California, Los Angeles, CA, USA

PCN108
C8
COST-EFFECTIVENESS OF NIRAPARIB AND OLAPARIB AS MAINTENANCE THERAPY FOR PATIENTS WITH PLATINUM SENSITIVE< RECURRENT OVARIAN CANCER
Zhong L1, Tran AT1, Tomasino T1, Smith JA2, Nugent EK3
1Texas A&M University, College Station, TX, USA, 2The University of Texas Health Science Center at Houston, Houston, TX, USA, 3McGovern Medical School at UTHealth, Houston, TX, USA

PCN109
C9
EFFICIENCY OF NIMOTUZUMAB TREATMENT IN PATIENTS WITH HEAD AND NECK CANCER IN CUBA.
Pérez L1, Collazo MM2, Escobar N1
1Center of Molecular Immunology, Havana, Cuba, 2National Institute of Hygiene, Epidemiology and Microbiology, Havana, Cuba

PCN110
C10
COST EFFECTIVENESS OF ANTI-PD-1/PD-L1 TREATMENTS: SYSTEMATIC REVIEW OF PUBLISHED STUDIES
Aggarwal S1, Topaloglu O1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN111
C11
COST-EFFECTIVENESS EVALUATION OF ENZALUTAMIDE AND ABIRATERONE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PROGRESSING AFTER DOCETAXEL IN THE MEXICAN PUBLIC HEALTHCARE SYSTEM
Gay JG1, Schultz NM2, Braun S2
1T.I. Salud, Mexico, Mexico, 2Astellas Pharma Inc., Northbrook, IL, USA

PCN112
C12
ICERS ARE NOT ALL THE SAME. HOW COST-EFFECTIVENESS ESTIMATES DIFFER BETWEEN THE UK AND US
Hewitt C1, Foxon G1, Craddy P2, Chunara F1
1Remap Consulting, Cheshire, UK, 2Remap Consulting, Zug, Switzerland

PCN113
C13
ECONOMIC EVALUATION OF THE USE OF LINEAR ACCELERATOR OF ELECTRONS FOR INTRAOPERATIVE RADIOTHERAPY IN THE TREATMENT OF RECTAL CANCER IN MEXICO
Escobar Juárez Y, Sinta Cortes G, Soto Molina H
HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico

PCN114
C14
THE COST EFFECTIVENESS ANALYSIS OF PD-1 AND PD-L1 AGENTS COMPARED WITH DOCETAXEL FOR SECOND-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Bae-Shaaw YH, Hay JW
University of Southern California, Los Angeles, CA, USA

PCN115
C15
COST-EFFECTIVENESS OF REGULAR UTILIZATION OF ZOLEDRONIC ACID FOR DEVELOPED BONE METASTASES FROM ADVANCED LUNG CANCER IN CHINESE PATIENTS
Yu Z1, Liu Y1, Cui Y1, Ma R1, Liu C2, Qian J2, Zhan H3, Chen W4, Ren Y1, Liu H1
1Liaoning Cancer Hospital and Institute, Shenyang, China, 2Novartis Pharmaceuticals (China) Oncology, Beijing, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting Ltd, Mississauga, ON, Canada

PCN116
C16
COST-EFFECTIVENESS ANALYSIS OF RUCAPARIB MAINTENANCE TREATMENT FOR RECURRENT OVARIAN CARCINOMA AFTER RESPONSE TO PLATINUM THERAPY
Chin L, Carlson JJ
University of Washington, Seattle, WA, USA

PCN117
C17
COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
Freire V1, Cabezas M2, Salcedo E2, Albert A3
1Mediko-geneticheskiy Nauchnyytsentr, Moscu, Russian Federation, 2Pontifical Catholic University, Quito, Ecuador, 3Liege University, Liege, Belgium

PCN118
C18
COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2− ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
Djambazov S1, Slavchev G1, Mitova R1, Velchev M2, Vekov T3
1HTA Ltd., Sofia, Bulgaria, 2Pfizer Luxembourg SARL Branch Bulgaria, Sofia, Bulgaria, 3Medical University Pleven, Pleven, Bulgaria

PCN119
C19
ECONOMIC EVALUATION OF FIVE VERSUS TEN YEARS OF TAMOXIFEN FOR HORMONE RECEPTOR POSITIVE EARLY STAGE BREAST CANCER
WU L
China Pharmaceutical University, Jiangsu, China

PCN120
C20
A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB+FOLFIRI COMPARED TO BEVACIZUMAB+FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR
Evans R1, Aggarwal H2, Takundwa R1, Chin S2, Fenwick E3
1ICON plc, Abingdon, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3ICON Health Economics, ICON plc, Abingdon, UK

PCN121
C21
COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
Yang F1, Kumar A2, Rojanasarot S2, Schommer JC2, Shao R1
1China Pharmaceutical University, Nanjing, China, 2College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

PCN122
C22
COST-EFFECTIVENESS ANALYSIS OF CAPECITABINE MONOTHERAPY VERSUS CAPECITABINE PLUS OXALIPLATIN IN ELDERLY PATIENTS WITH ADVANCED GASTRIC CANCER
Tan C1, Peng J2, Zeng X1, Liu S2
1The Second Xiangya Hospital of Central South University, Changsha, China, 2The Third Xiangya Hospital of Central South University, Changsha, China

PCN123
C23
COST-EFFECTIVENESS OF REGULAR UTILIZATION OF ZOLEDRONIC ACID FOR DEVELOPED BONE METASTASES FROM ADVANCED BREAST CANCER IN CHINESE PATIENTS
Cui Y1, Zhang Q1, Zhang W1, He M1, Zhao C1, Liu C2, Qian J2, Zhan H3, Chen W4, Zheng W5
1Liaoning Cancer Hospital and Institute, Shenyang, China, 2Novartis Pharmaceuticals (China) Oncology, Beijing, China, 3Changsha Normin Health Technology Ltd, Changsha, China, 4Normin Health Consulting Ltd, Mississauga, ON, Canada, 5Liaoning Cancer Hospital and Institute of China Medical University, Shenyang, Liaoning, China

PCN124
C24
COST-EFFECTIVENESS OF CETUXIMAB FOR LEFT-SIDE METASTATIC COLORECTAL CANCER IN ECUADOR
Cabezas M1, Freire V2, Salcedo E1, Albert A3
1Pontifical Catholic University, Quito, Ecuador, 2Mediko-geneticheskiy Nauchnyytsentr, Moscu, Russian Federation, 3Liege University, Liege, Belgium

PCN125
C25
COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
Salcedo E1, Freire V2, Cabezas M1, Albert A3
1Pontifical Catholic University, Quito, Ecuador, 2Mediko-geneticheskiy Nauchnyytsentr, Moscu, Russian Federation, 3Liege University, Liege, Belgium

PCN126
C26
COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
Cabezas M1, Freire V2, Salcedo E1, Albert A3
1Pontifical Catholic University, Quito, Ecuador, 2Mediko-geneticheskiy Nauchnyytsentr, Moscu, Russian Federation, 3Liege University, Liege, Belgium

PCN127
C27
COST-EFFECTIVENESS OF NIRAPARIB VERSUS ROUTINE SURVEILLANCE AND OLAPARIB FOR THE MAINTENANCE TREATMENT OF ADULT PATIENTS WITH OVARIAN CANCER IN THE UNITED STATES
Fisher M, Guy H, Walder L
FIECON, St Albans, UK

PCN128
C28
ECONOMIC VALUE OF GENETIC TESTING FOR CANCER DRUGS WITH CLINICALLY RELEVANT DRUG-GENE ASSOCIATIONS: A SYSTEMATIC LITERATURE REVIEW
Faruque F, Noh H, Onukwugha E
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN129
C29
COST-EFFECTIVENESS OF SHORT-COURSE RADIOTHERAPY COMPARED TO LONG-COURSE CHEMORADIOTHERAPY IN THE TREATMENT OF STAGE III RECTAL CANCER PATIENTS FROM THE US SOCIETAL PERSPECTIVE
Cohen BG, Hay J, Barzi A
University of Southern California, Los Angeles, CA, USA

PCN130
C30
COST-EFFECTIVENESS ANALYSIS OF SORAFENIB FOR FIRST-LINE UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CHINA
Zhou T1, Li HC1, Sun W2, Ma A1
1China Pharmaceutical University, Nanjing, China, 2Bayer Healthcare Co., Ltd., Beijing, China

PCN131
C31
COST-EFFECTIVENESS OF CRIZOTINIB, CERITINIB, AND ALECTINIB AS FIRST-LINE TREATMENTS FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) METASTATIC NON-SMALL CELL LUNG CANCER
Xuan S1, Ma J2
1University of Southern California, Los Angeles, CA, USA, 2University of Utah, Salt Lake City, UT, USA

PCN132
C32
LIFETIME COST-EFFECTIVENESS OF ADJUVANT EXTERNAL BEAM WHOLE BREAST IRRADIATION (EBWBI) IN ESTROGEN RECEPTOR POSITIVE (ER+) EARLY-STAGE BREAST CANCER (ESBC) WOMEN: CARDIOTOXICITY CONSIDERATION
Ezendu KO1, Diaby V2, Ali AA3
1Florida A&M University, TALLAHASSEE, FL, USA, 2University of Florida, Gainesville, FL, USA, 3Florida A & M University, Tallahassee, FL, USA

PCN133
C33
COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE FOLFIRI COMBINED WITH CETUXIMAB OR BEVACIZUMAB IN PATIENTS WITH RAS WILD-TYPE LEFT-SIDED METASTATIC COLORECTAL CANCER
Zeng X1, Han J2, Tan C1, Huang J2
1The Second Xiangya Hospital of Central South University, Changsha, China, 2Xiangya Hospital of Central South University, Changsha, China

PCN134
C34
COST-EFFECTIVENESS OF OSIMERTINIB IN NSCLC PATIENTS WHO PROGRESSED AFTER EGFR-TKI: EVIDENCE IN CHINA
Guan HJ1, Liu GG2, Wang YN1, Sheng YN1, Li HC3
1PKU China Center for Health Econimic Research, Beijing, China, 2National School of Development, Peking University, Beijing, China, 3China Pharmaceutical University, Nanjing, China

PCN135
C35
COST-EFFECTIVENESS ANALYSIS OF ADDING PALBOCICLIB AS A SECOND-LINE ENDOCRINE THERAPY OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER FROM US AND CHINESE PERSPECTIVES
Wan X1, Zhang Y2, Tan C1, Zeng X1, Peng L1
1The Second Xiangya Hospital of Central South University, Changsha, China, 2School of Mathematics and Statistics, Central South University, Changsha, China

PCN136
C36
COST EFFECTIVENESS ANALYSIS OF AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH >30% BLASTS AND WHO ARE NOT CANDIDATE FOR CURATIVE-INTEND CHEMOTHERAPY
Villeneuve PJ, Coyle D
University of Ottawa, Ottawa, ON, Canada

PCN137
C37
ECONOMIC EVALUATION OF THE MOBILE ELECTRON ACCELERATOR FOR INTRAOPERATIVE RADIOTHERAPY IN PATIENTS WITH BREAST CANCER
Soto-Molina H1, Escobar Juárez Y2, Sanchez-Trejo K3
1Health Solutions, Mexico City, Mexico, 2HS Estudios Farmacoeconómicos S.A. de C.V., Mexico City, Mexico, 3Independet consultant, Mexico, Mexico

PCN138
C38
COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB FOR THIRD-LINE METASTATIC COLORECTAL CANCER (MCRC) COMPARED TO CETUXIMAB PLUS IRINOTECAN IN CHINA
Liu J1, Zhu S1, Sun W2, Tao L3, Xiao D1, Xuan J3
1Shanghai Centennial Scientific Co., Ltd, Shanghai, China, 2Bayer Healthcare Co., Ltd., Beijing, China, 3Sun Yat-sen University, Guangzhou, China

PCN139
C39
ECONOMIC EVALUATION OF RAMUCIRUMAB AS SECOND-LINE CHEMOTHERAPY FOR PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA IN CHINA
Luo X, Peng L, Tan C, Wan X, Zeng X
The Second Xiangya Hospital of Central South University, Changsha, China

PCN140
C40
COST-EFFECTIVE STUDY OF ALECTINIB IN TREATING CRIZOTINIB-FAILED ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN TAIWAN
Liao C1, Wang C2, Chan KA3, Hsiao F4
1Social & Administrative Sciences in Pharmacy Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA, 2School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan, 3Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan, 4Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan

PCN141
C41
TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN142
C42
HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH MULTIPLE MYELOMA: ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN143
C43
TRENDS IN HOSPITALIZATION LENGHT OF STAY AND COSTS IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL): ANALYSIS OF US NATIONAL IN-PATIENT DATA FOR 2015
Aggarwal S1, Kumar S2, Topaloglu O1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PCN144
C44
EXPANDED GENOMIC TESTING FOR PEDIATRIC CANCERS IS CLINICALLY IMPACTFUL BUT REIMBURSEMENT LAGS BEHIND
Oberg JA1, Sireci AN1, Hsiao SJ1, Pendrick D1, Turk AT1, Chung WK1, Sulis ML1, Kung AL2, Mansukhani MM1, Glade Bender JL1
1Columbia University, New York, NY, USA, 2Memorial Sloan Kettering Cancer Center, New York, NY, USA

PCN145
C45
ECONOMIC VALUE OF NEXT GENERATION SEQUENCING PANELS IN ONCOLOGY - A MARKET DEVELOPMENT PERSPECTIVE
Chaudhari V1, Schroeder B2, Pal P2
1University of the Sciences, Philadelphia, PA, USA, 2Illumina Inc, San Diego, CA, USA

CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN146
C46
IDENTIFYING ADHERENCE BARRIERS TO ORAL ENDOCRINE THERAPY (OET) AMONG BREAST CANCER PATIENTS
Paranjpe R, Trivedi M, Abughosh S
University of Houston, Houston, TX, USA

PCN147
D1
ADHERENCE OF OUTPATIENT CANCER PATIENTS TO ORAL ONCOLYTIC MEDICATIONS PROVIDED BY A SPECIALTY PHARMACY
Feinberg BA1, Burruss RA2, Arikian V3, Jaster R1, Oleru K1, Traurig T2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health Specialty Pharmacy, Columbia, MD, USA, 3SUNY Downstate Medical Center, Brooklyn, NY, USA

PCN148
D2
THE ASSOCIATION BETWEEN PATIENT-PROVIDER COMMUNICATION AND BREAST CANCER SCREENING DISPARITIES
Crowe J1, Zhang J2
1Consumer Financial Protection Bureau, Chicago, IL, USA, 2The University of Chicago, Chicago, IL, USA

PCN149
D3
A 2-ARM RANDOMIZED PILOT STUDY TO EVALUATE THE IMPACT OF A MOBILE HEALTH APPLICATION ON MEDICATION ADHERENCE IN PATIENTS ON ORAL ANTI-CANCER MEDICATIONS.
Fischer N, Agboola S, Palacholla R, Atif M, Jethwani K, Kvedar J
Partners Connected Health, Boston, MA, USA

PCN150
D4
IMPACT OF NON- ADHERENCE TO ANTIEMETIC GUIDELINES ON THE INCIDENCE OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING AND QUALITY OF LIFE: FINDINGS FROM RESOURCE LIMITED SETTINGS.
Ayele AA
University of Gondar, gondar, Ethiopia

PCN151
D5
LONGITUDINAL ANALYSIS OF ADJUSTED EQ-5D UTILITY SCORE AT BASELINE, PROGRESSION-FREE SURVIVAL, AND PROGRESSION FOR LENVATINIB VERSUS SORAFENIB
Hudgens S1, Copher R2, Meier G2
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

PCN152
D6
RELATIONSHIP BETWEEN HEALTH STATE AND PATIENT REPORTED OUTCOME IN CUTANEOUS T-CELL LYMPHOMA: AN EXPLORATORY ANALYSIS
Hudgens S1, Dunn J2, Floden L1, Spencer G3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Kyowa Kirin, Inc., Bedminster, NJ, USA, 3Kyowa Kirin, Inc., Galashiels, UK

PCN153
D7
SYSTEMATIC LITERATURE REVIEW (SLR) OF HEALTH STATE UTILITY VALUES (HSUV) IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTANT (EGFR-MUTANT) NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS PREVIOUSLY TREATED WITH TARGETED THERAPIES
Shor A1, Forsythe A1, Li S2, Galaznik A2
1Purple Squirrel Economics, New York, NY, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

PCN154
D8
REAL-WORLD EQ-5D-5L UTILITY VALUES IN PATIENTS WITH MELANOMA DERIVED USING A DIGITAL ‘BRING YOUR OWN DEVICE’ PLATFORM
Larkin J1, Nuttal G2, Cannon D2, Au L1, Spain L1, Hunter N1, Turajlic S1, Nixon A3, Kousoulakou H4, Larkin M4, Wiseman T1
1The Royal Marsden NHS Foundation Trust, London, UK, 2Melanoma UK, Oldham, UK, 3Chilli Consultancy, Salisbury, UK, 4Vitaccess Ltd, Oxford, UK

PCN155
D9
PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2– ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
Mitra D1, Darden C2, McSorley D2, Davis K2, Band J2, Iyer S1
1Pfizer, Inc, New York, NY, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PCN156
D10
IMPACTS OF TIME SPENT ON RITUXIMAB INFUSION ON PATIENT SATISFACTION, STRESS, EMPLOYMENT, AND CAREGIVER BURDEN
Fisher MD1, Wallick CJ2, Miller PJ1, Walker MS1, Lash S2, Dawson KL2, Reyes CM2
1Vector Oncology, Memphis, TN, USA, 2Genentech, Inc., South San Francisco, CA, USA

PCN157
D11
PREFERENCES FOR AML TREATMENTS - USING A DISCRETE CHOICE EXPERIMENT TO INFORM A COMMUNITY LED PATIENT-FOCUSED DRUG DEVELOPMENT INITIATIVE
Janssen E1, Oakes A2, O'Donoghue B3, Bridges JF4
1ICON, Gaithersburg, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 3The Leukemia & Lymphoma Society, Washington, DC, DC, USA, 4The Ohio State University, Columbus, OH, USA

PCN158
D12
ATTRIBUTE LEVEL EFFECT ON MEASUREMENT OF PREFERENCES FOR LUNG CANCER TREATMENT – RESULTS FROM A DISCRETE CHOICE EXPERIMENT
Janssen E1, Basu Roy U2, Ferris A2, Bridges JF3
1ICON, Gaithersburg, MD, USA, 2LUNGevity Foundation, Bethesda, MD, USA, 3The Ohio State University, Columbus, OH, USA

PCN159
D13
A COMPARISON OF PATIENT AND CAREGIVER WORRIES FOR ACUTE MYELOID LEUKEMIA
Oakes AH1, Seo J2, Janssen E3, O'Donoghue B4, Bridges JF5
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Evidera, Baltimore, MD, USA, 3ICON, Gaithersburg, MD, USA, 4The Leukemia & Lymphoma Society, Washington, DC, DC, USA, 5The Ohio State University, Columbus, OH, USA

PCN160
WITHDRAWN

PCN161
D14
EXAMINATIONS OF ATTITUDES OF ROMANY MINORITY WOMEN TOWARDS CERVICAL CANCER SCREENING
Pakai A1, Horváthné Kívés Z2, Szabó-Gabara K2, Oláh A2, Szabó L2, Karácsony I3, Boncz I2, Endrei D2, Vajda R2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Szombathely, Hungary

PCN162
D15
EVALUATION OF THE DISEASE-SPECIFIC ITEMS ON THE EORTC IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIB OR SORAFENIB
Hudgens S1, Copher R2, Meier G2
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA

PCN163
D16
IDENTIFYING CANCER TRIALS THAT INCORPORATE PATIENT-REPORTED OUTCOME MEASURES: COMPARING FDA STUDY REPORTS TO CLINICALTRIALS.GOV
Roydhouse JK1, Carneiro Leao I2, King-Kallimanis B1, Kluetz PG1
1FDA, Silver Spring, MD, USA, 2U.S. Food and Drug Administration, Silver Spring, MD, USA

PCN164
D17
SYMPTOMS AND IMPACTS IN ADVANCED/METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER: FINDINGS FROM QUALITATIVE PATIENT INTERVIEWS
Morlock R1, Holmstrom S2, Hawryluk E3, Bruce R3, Crooks P3, Paty J3
1Astellas Pharma Global Development, Inc., Northbrook, IL, USA, 2Astellas Pharma Europe, B.V., Leiden, The Netherlands, 3IQVIA Consulting Services, New York, NY, USA

PCN165
D18
PATIENT-REPORTED OUTCOME USE AND COMPLETION INFORMATION IN NON-RANDOMIZED CANCER TRIALS
Roydhouse JK, King-Kallimanis BL, Howie LJ, Singh H, Kluetz PG
FDA, Silver Spring, MD, USA

PCN166
D19
AWARENESS, KNOWLEDGE AND ATTITUDES TOWARDS CERVICAL CANCER AMONGST HIV-POSITIVE WOMEN RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIA
Adibe MO, Aluh O, Igboeli NU
University of Nigeria, Nsukka, Nsukka, Nigeria

PCN167
D20
PATIENT REPORTED OUTCOMES IN METASTATIC RENAL CELL CARCINOMA PATIENTS RECEIVING PAZOPANIB IN A COMMUNITY ONCOLOGY SETTING
Fisher MD1, Ghate SR2, Miller PJ1, Walker MS1, Ferrusi IL2, Agarwal N3
1Vector Oncology, Memphis, TN, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA

PCN168
D21
EVALUATION OF MEANINGFUL CHANGE IN PATIENT-RELATED OUTCOMES FOR PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
Hudgens S1, Dunn J2, Floden L1, Spencer G3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Kyowa Kirin, Inc., Bedminster, NJ, USA, 3Kyowa Kirin, Inc., Galashiels, UK

PCN169
D22
TAKING THE BURDEN OUT OF SYMPTOM REPORTING IN PATIENTS WITH MELANOMA USING A DIGITAL REAL-WORLD EVIDENCE PLATFORM
Au L1, Nuttal G2, Cannon D2, Spain L1, Hunter N1, Turajlic S1, Nixon A3, Kousoulakou H4, Larkin M4, Larkin J1, Wiseman T1
1The Royal Marsden NHS Foundation Trust, London, UK, 2Melanoma UK, Oldham, UK, 3Chilli Consultancy, Salisbury, UK, 4Vitaccess Ltd, Oxford, UK

PCN170
D23
WITHDRAWN

PCN171
D24
BENEFIT OF ABIRATERONE ACETATE PLUS PREDNISONE (AA+P) ADDED TO ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH HIGH-RISK, NEWLY DIAGNOSED METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC): POST HOC ANALYSIS OF EQ-5D-5L FROM THE LATITUDE STUDY
Metin H1, McQuarrie K2, Thilakarathne P3, Diels J4, Ito T5, Li T6, Sulur G7, Chi KN8, Fizazi K9
1Janssen-Cilag GmbH, North Rhine-Westphalia, Germany, 2Janssen Research & Development, Spring House, PA, USA, 3Janssen-Cilag, Beerse, Belgium, 4Janssen Pharmaceutica NV, Beerse, Belgium, 5Janssen-Cilag, UK, High Wycombe, UK, 6Janssen Global Services, Raritan, NJ, USA, 7Janssen Research & Development, Los Angeles, CA, USA, 8BC Cancer Agency-Vancouver Centre, Vancouver, BC, Canada, 9Gustave Roussy, University of Paris Sud, Villejuif Cedex, France

PCN172
E1
VALIDITY OF PATIENT-REPORTED OUTCOMES FROM COLUMBUS, A RANDOMIZED OPEN LABEL PHASE III CLINICAL TRIAL OF ENCORAFENIB PLUS BINIMETINIB VS VEMURAFENIB IN ADVANCED BRAF-MUTANT MELANOMA
Rahhali N1, Chalem Y1, Niemira J2, van Gils CW3, Blome C4, Gerlier L3
1Pierre Fabre, Boulogne-Billancourt, France, 2IQVIA, Cambridge, MA, USA, 3IQVIA, Zaventem, Belgium, 4University Medical Center Hamburg-Eppendorf, Hambourg, Germany

PCN173
E2
PATTERNS OF USE AND QUALITY OF LIFE (QOL) ASSOCIATED WITH THE UTILIZATION OF ANTIDEPRESSANTS AMONGST CANCER PATIENTS WITH DEPRESSION
Parab PN, Nadpara PA, Carroll NV, Mays DP
Virginia Commonwealth University, Richmond, VA, USA

PCN174
E3
ASSESSMENT OF CHANGE IN QUALITY OF LIFE (QOL), CARCINOID SYNDROME (CS) SYMPTOMS, AND HEALTH CARE RESOURCE UTILIZATION (HRU) IN CS PATIENTS TREATED WITH SOMATOSTATIN ANALOGS (SSA) -- RESULTS FROM LONGITUDINAL PATIENT SURVEYS
Huynh L1, Bhak R1, Narkhede S1, Beaumont JL2, Halperin DM3, Cai B4, Duh MS1, Neary MP4, Chang R1, Cella D5
1Analysis Group, Inc., Boston, MA, USA, 2Terasaki Research Institute, Los Angeles, CA, USA, 3University of Texas MD Anderson Cancer Center, Houston, TX, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Northwestern University, Chicago, IL, USA

PCN175
E4
QUALITY OF LIFE OF PATIENTS WITH CANCER UNDERGOING CHEMOTHERAPY IN BELO HORIZONTE HOSPITALS.
Cherchiglia ML, Moreira DP, Simino GP
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

PCN176
E5
DETERMINATION OF HEALTH-RELATED QUALITY OF LIFE BY USING EQ-5D 3L IN CANCER PATIENTS IN SWAT, KHYBER PAKHTUNKHWA PAKISTAN
Ali Khan/ A1, Haq N2, Nasim A2, Riaz S3, Zarak MS4
1Department of Pharmacy Practice, University of Balochistan, Quetta, Pakistan, 2University of Balochistan, Quetta, Pakistan, 3Akson College of Pharmacy, Mirpur, Pakistan, 4Bolan Medical College Quetta, Quetta, Pakistan

CANCER - Health Care Use & Policy Studies
PCN177
E6
VARIATION IN LOCOREGIONAL TREATMENT OF STAGE I – II BREAST CANCER BY BREAST SUBTYPE IN NONELDERLY ADULT WOMEN
Voelker J1, Alcusky M2, Singer D1, Mitchell E3, Delgado D1
1Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA, 2University of Massachusetts Medical School, Worcester, MA, USA, 3Sidney Kimmel Cancer Center of Thomas Jefferson University, Philadelphia, PA, USA

PCN178
E7
ENVIRONMENTAL SCAN OF HIGH RISK BREAST CANCER PROGRAMS
Hassen DA1, Snyder SR2, Rahm A3, Jarrett DL4, Crissinger S4, Hao Q1, Leeming R5
1Geisinger Department of Epidemiology and Health Services Research, Danville, PA, USA, 2Geisinger Department of Epidemiology and Health Services Research, Forty Fort, PA, USA, 3Geisinger Genomic Medicine Institute, Danville, PA, USA, 4Geisinger Center for Health Research, Danville, PA, USA, 5Geisinger Medical Center, Danville, PA, USA

PCN179
E8
A FOOT IN THE DOOR OR ONE FOOT IN THE GRAVE? THE ROLE OF REAL WORLD EVIDENCE IN CANCER DRUGS FUND RE-APPRAISALS
Walsh S, Roibu C, Macaulay R
PAREXEL International, London, UK

PCN180
E9
OFF-LABEL CHEMOTHERAPY IN CANCER: A REVIEW OF CURRENT COVERAGE LANDSCAPE AND REIMBURSEMENT CONSIDERATIONS.
Kuvadia HV1, Nayak D2, Shrikhande M3, Nayak R4
1St. John's University, Jamaica, NY, USA, 2ST.JOHNS UNIVERSITY, QUEENS, NY, USA, 3St.Johns University, Jamaica, NY, USA, 4St. John's University, Queens, NY, USA

PCN181
E10
UTILIZATION AND IMPACT OF VALUE ASSESSMENT FRAMEWORKS ON PAYER DECISIONS REGARDING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPIES
Nguyen VB, Kanaskar A, Migliaccio-Walle K, Shields K
Xcenda, LLC, Palm Harbor, FL, USA

PCN182
E11
PROFILES OF NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNO-ONCOLOGY THERAPIES IN THE UNITED STATES AND WESTERN EUROPE
Shah-Manek B1, Karki C2, Whitmire SM2, Ilacqua J3, Wriede V4
1Ipsos Healthcare, San Francisco, CA, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, Mahwah, NJ, USA, 4Ipsos Healthcare, Boston, MA, USA

PCN183
E12
USE OF BIOMARKER TESTING IN HEAD AND NECK CANCERS IN THE UNITED STATES AND EU5
Noone JM1, Shah-Manek B2, Karki C1, Whitmire SM1, Clark LA1, Patel RP1, Ilacqua J3, Wriede V4
1Ipsos Healthcare, New York, NY, USA, 2Ipsos Healthcare, San Francisco, CA, USA, 3Ipsos Healthcare, Mahwah, NJ, USA, 4Ipsos Healthcare, Boston, MA, USA

PCN184
E13
CANCER MORTALITY TRENDS IN BRAZIL AND MEXICO
Julian GS1, Carneseca EC2, Sicchieri MP2, Pomerantz D3, Clark OA1
1Evidências - Kantar Health, São Paulo, Brazil, 2Proestat, Ribeirão Preto, Brazil, 3Kantar Health, Horsham, PA, USA

PCN185
E14
THERAPY FOR GLIOMA: INDIAN MARKET OVERVIEW
Mathew MP1, Makadia K2, Gurjar K3
1National Institute of Pharmaceutical education and research, Mohali, India, 2NIPER, Mohali, India, 3NIPER, Ahmedabad, Gujarat, India

PCN186
E15
THE GROWING NUMBER OF HIGH-COST ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPS) POSE UNPRECEDENTED PRICING AND FUNDING CHALLENGES TO CURRENT MODELS OF HEALTHCARE
Del Carlo A1, Paglia R1, Carter EA1, Schwartz J1, Dyson S2, Areteou T2, Foy C2
1Consulting at McCann Health, New York, NY, USA, 2Consulting at McCann Health, London, UK

PCN187
E16
PATTERNS OF SECOND-LINE (2L) TREATMENT FOR METASTATIC UROTHELIAL CANCER (MUC) IN CANADA
Jaffe DH1, DeCongelio M2, Li VW2, Lakhdari K3, Goulden S4, Gooden KM5
1Kantar Health, Tel Aviv, Israel, 2Kantar Health, New York, NY, USA, 3Bristol-Myers Squibb Canada, Montréal, QC, Canada, 4Bristol-Myers Squibb, Uxbridge, UK, 5Bristol-Myers Squibb, Lawrenceville, NJ, USA

PCN188
E17
EMERGENT THERAPIES AND EGFR MUTATION TESTING IN NON-SMALL CELL LUNG CANCER: REAL-WORLD PRACTICES
Chen L, Herrington JD, Godley PJ, Rao A, Henderson SM
Baylor Scott & White Health, Temple, TX, USA

PCN189
E18
HEPATOCELLULAR CARCINOMA IN THE BRAZILIAN PUBLIC HEALTH SYSTEM: A BURDEN OF ILLNESS MODEL
Ramos NB1, Cruz AT1, Nakada C1, Campos DF1, Rigolon J2, Ferraz AF2
1Bayer SA, São Paulo, Brazil, 2IQVIA, São Paulo, Brazil

PCN190
E19
REAL-WORLD TREATMENT PATTERNS AND CARE PATHWAYS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Lam J1, Yang C2, Kaiser C2, Wong W2
1University of Southern California (USC), Los Angeles, CA, USA, 2Genentech, Inc., South San Francisco, CA, USA

PCN191
E20
VALUE-BASED CARE IN ONCOLOGY: CHALLENGES AND BARRIERS AMONGST COMMUNITY ONCOLOGISTS
Nabhan C, Smith Y, Klink A, Kish J, Feinberg B
Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN192
E21
COMMUNITY ONCOLOGY PERCEPTIONS AND VIEWS ON GENOMIC TESTING IN THE ERA OF PRECISION ONCOLOGY
Nabhan C, Smith Y, Klink A, Kish J, Feinberg B
Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN193
E22
INFLUENCE OF CRITICAL DISEASE INSURANCE (CDI) POLICY ON PEMETREXED ADHERENCE AMONG THE FIRST-LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN ZHEJIANG PROVINCE OF CHINA
Zhou JY1, Li YP1, Xie CY1, Yuan Y2, Xia B3, Wang LM4, Wang K2, Chen Y5, Yao LD5, Zhan LJ5, Wen Y6, Ma SL4
1The first provincial Wenzhou hospital of Zhejiang. Wenzhou, Wen Zhou, China, 2The second affiliated hospital, Zhejiang University School of Medicine, Hang Zhou, China, 3Hangzhou cancer hospital, Hang Zhou, China, 4Hangzhou first people’s hospital., Hang Zhou, China, 5Lilly Suzhou Pharmaceutical Co., Ltd Shanghai Branch, Shang Hai, China, 6Medbanks company, Bei Jing, China

PCN194
E23
EVIDENCE DRIVEN CANCER DRUG APPROVALS IN PHASE II VERSUS PHASE III CLINICAL TRIALS WITHIN A SINGLE-PAYER PUBLIC HEALTHCARE SYSTEM
Wang Y, Ellis P
McMaster University, Hamilton, ON, Canada

PCN195
E24
A MAPPING AND ANALYSIS OF NATIONAL ACCELERATED ACCESS PATHWAYS FOR CANCER DRUGS
Mills M, Tzouma V, Kanavos P
London School of Economics and Political Science, London, UK

PCN196
F1
THE LONG-TERM SOCIAL VALUE OF BETTER TARGETING G-CSF THERAPY TO CANCER PATIENTS AT RISK OF FEBRILE NEUTROPENIA
Ward AS1, Kabiri M2, Yucel A3, Silverstein AR1, van Eijndhoven E4, Bowers C3, Bensink M5, Goldman DP6
1Precision Health Economics, Oakland, CA, USA, 2Precision Health Economics, Austin, TX, USA, 3Amgen, Thousand Oaks, CA, USA, 4Precision Health Economics, Los Angeles, CA, USA, 5Amgen Inc, Thousand Oaks, CA, USA, 6University of Southern California, Los Angeles, CA, USA

PCN197
F2
THE IMPACT OF REGULATORY ACCELERATED APPROVAL SCHEMES AND HTAS ON ACCESS TO NEW ONCOLOGY MEDICINES: EVIDENCE FROM 11 COUNTRIES
Kanavos P, Tzouma V, Flannelly C
London School of Economics and Political Science, London, UK

PCN198
F3
UTILIZATION PATTERNS OF THE FIRST US BIOSIMILAR, FILGRASTIM-SNDZ, OBSERVED BETWEEN 2015 AND 2017 IN A MEDICAL TRANSCRIPTION DATABASE
Smoyer K1, Ó Hartaigh B2
1Envision Pharma Group, Philadelphia, PA, USA, 2Envision Pharma Group, Southport, CT, USA

PCN199
F4
REAL-WORLD DATA ANALYSIS OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) TREATMENT DECISIONS WITH THE INTRODUCTION OF NEWER TREATMENT OPTIONS
Scott J, Concepcion R, Garofalo D, Verma-Kurvari S, Xu B, Montgomery J
Integra Connect, West Palm Beach, FL, USA

PCN200
F5
WITHDRAWN

PCN201
F6
TRASTUZUMAB UPTAKE IN HER2-POSITIVE BREAST CANCER PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES
Martin AP1, Downing J1, Collins B2, Cochrane M3, Francis B2, Haycox A2, Alfirevic A1, Pirmohamed M1
1National Institute for Health Research, Collaborations for Leadership in Applied Health Research and Care, North West Coast (NIHR CLAHRC NWC), University of Liverpool, Liverpool, UK, 2University of Liverpool, Liverpool, UK, 3Liverpool John Moores University, Liverpool, UK

PCN202
F7
PRESCRIPTION PATTERN OF OPIOIDS AMONG PROSTATE CANCER PATIENTS OF VARIOUS RACIAL GROUPS
Shah CH, Xiao H
University of Florida, Gainesville, FL, USA

PCN203
F8
HOW WILL PAYERS MANAGE THE HIGH COST OF COMBINATIONS OF NEW ONCOLOGY AGENTS, AS MANY OF THESE THERAPIES BECOME THE PREFERRED TREATMENT OPTIONS TO OPTIMIZE PATIENT OUTCOMES?
Paglia R1, Del Carlo A1, Schwartz J1, Carter EA1, Foy C2, Dyson S2, Areteou T2
1Consulting at McCann Health, New York, NY, USA, 2Consulting at McCann Health, London, UK

PCN204
F9
WHAT IS THE FUTURE OF USING OUTCOMES-BASED CONTRACTS BETWEEN PAYERS AND PHARMACEUTICAL MANUFACTURERS TO GAIN MARKET ACCESS FOR ADVANCED ONCOLOGIC AND BIOLOGIC AGENTS?
Paglia R1, Blackham J1, Del Carlo A1, Schwartz J1, Carter EA1, Foy C2, Dyson S2, Areteou T2
1Consulting at McCann Health, New York, NY, USA, 2Consulting at McCann Health, London, UK

PCN205
F10
WHAT IS THE FUTURE OF INDICATION-BASED PRICING AND CONTRACTING (IBPC) FOR MARKET ACCESS OF NEW ONCOLOGIC AND BIOLOGIC AGENTS IN MAJOR GLOBAL MARKETS?
Paglia R1, Del Carlo A1, Carter EA1, Schwartz J1, Foy C2, Areteou T2, Dyson S2
1Consulting at McCann Health, New York, NY, USA, 2Consulting at McCann Health, London, UK

PCN206
F11
COMPARISON OF DOSE INTENSITY IN CLINICAL TRIAL AND REAL WORLD SETTINGS FOR NIRAPARIB
Parpos P, Bala M
TESARO, Inc., Waltham, MA, USA

PCN207
F12
ANTI-PD1 DRUGS: ARE THE REIMBURSED INDICATIONS OF THE MARKETING AUTHORIZATION RESPECTED?
Therasse C1, Paubel P2, Cordonnier A1, Fusier I1
1AP-HP, AGEPS, Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP); Health Law Institute, INSERM UMR S 1145, Paris Descartes ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France

PCN208
F13
ADJUVANT CHEMOTHERAPY USE FOR STAGE II COLON CANCER IN MEDICARE POPULATION
Jiao X, Zhang H, Barzi A
University of Southern California, Los Angeles, CA, USA

PCN209
F14
RELATIONSHIP OF HEALTH INSURANCE WITH TUMOR SIZE AND INITIAL SURGICAL TREATMENT AMONG WOMEN AGED 18-64 DIAGNOSED WITH MALIGNANT PHYLLODES TUMORS OF THE BREAST
Park L1, Delgado D2
1Thomas Jefferson University, vienna, VA, USA, 2Thomas Jefferson University, Johnstown, PA, USA

PCN210
F15
BARBEC(EU)D ONCOLOGY MARKET ACCESS – PART D(EU)X
Swilling NW, Chang S, Dev J, Xu A, Zhu M
Simon Kucher & Partners, Cambridge, MA, USA

PCN211
F16
PRICING, AVAILABILITY, AFFORDABILITY, PRICE COMPONENT OF ESSENTIAL ANTICANCER MEDICINES; A CASE IN ADDIS ABABA, ETHIOPIA
Tadesse N1, Fang Y2, Ewen M3
1Xian Jiaotong University, Center for Drug Safety & Policy Research, Xian, China, 2Xi'an Jiaotong University, Xi'an, China, 3Health Action International (HAI), Amesterdam, The Netherlands

PCN212
F17
ECONOMIC BURDEN OF RENAL CELL CARCINOMA AMONG OLDER ADULTS IN THE TARGETED THERAPY ERA
Kale HP, Mays DP, Nadpara PA, Slattum PW, Paul AK, Carroll NV
Virginia Commonwealth University, Richmond, VA, USA

PCN213
F18
ECONOMIC BURDEN OF LOCALLY ADVANCED OR METASTATIC MERKEL CELL CARCINOMA IN THE UNITED STATES: AN ANALYSIS OF ELECTRONIC HEALTH RECORDS
Kearney M1, Esposito D2, Penalvo J3, Russo L4, Yin R2, Lyons J2, Lanes S2, Bharmal M1
1Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 2Safety and Epidemiology, HealthCore, Inc., Andover, MA, USA, 3Global Epidemiology, Merck KGaA, Darmstadt, Germany, 4Pfizer, Inc, Collegeville, PA, USA

PCN214
F19
LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA IN THE UNITED STATES: ECONOMIC BURDEN AND HEALTHCARE UTILIZATION
Kearney M1, Esposito D2, Russo L3, Penalvo J4, Yin R2, Lyons J2, Lanes S2, Bharmal M1
1Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 2Safety and Epidemiology, HealthCore, Inc., Andover, MA, USA, 3Pfizer, Inc, Collegeville, PA, USA, 4Global Epidemiology, Merck KGaA, Darmstadt, Germany

PCN215
F20
EVALUATING THE BURDEN OF PROSTATE CANCER ON HEALTHCARE UTILIZATION,COST AND HEALTH STATUS USING MEDICAL EXPENDITURE PANEL SURVEY: A PROPENSITY MATCHED SCORE ANALYSIS
Desai RA, Sonawane K
University of Florida, Gainesville, FL, USA

PCN216
F21
TREATMENT PATTERN AND DIRECT MEDICAL COSTS AMONG PATIENTS WITH LUNG CANCER IN CHINA
Yu N1, Feng X1, Ye J2, Zhang J3
1Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 2Beijing North Medical & Health Economic Research Center, Beijing, China, 3China Health Insurance Research Association, Beijing, China

PCN217
F22
TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS BY LINE OF THERAPY IN NEWLY DIAGNOSED MERKEL CELL CANCER PATIENTS IN THE UNITED STATES
Kearney M1, Boutmy E1, Locker M2, Penalvo J1, Bharmal M1
1Merck KGaA, Darmstadt, Germany, 2EMD Serono, Billerica, MA, USA

PCN218
F23
COST EFFECTIVE ONLY AT A ZERO PRICE: A REAL-TIME SCENARIO IN UNTREATED BRAF V600 MUTATED METASTATIC MELANOMA?
Borissov BN1, Hanna E2, Auquier P2, Dorey J2, Toumi M3
1Prescriptia Ltd, Sofia, Bulgaria, 2Creativ-Ceutical, Paris, France, 3Aix-Marseille University, Marseille, France

PCN219
F24
UNITED STATES HEALTH PLAN CANCER CONCERNS IN 2018
Brook RA1, Carlisle JA2, Smeeding JE3
1The JeSTARx Group & TPG-NPRT, Newfoundland, NJ, USA, 2TPG-NPRT, Glastonbury, CT, USA, 3The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

PCN220
G1
THE IMPACT OF MEDICARE PART D DRUG COVERAGE ON TOTAL PRESCRIPTION DRUG EXPENDITURES AMONG CANCER PATIENTS IN 2014
Ma S
Brandeis University, Waltham, MA, USA

PCN221
G2
ANALYZE THE LIVER CANCER INPATIENTS COSTS DISTRIBUTION WITH BASIC MEDICAL INSURANCE SCHEME FOR EMPLOYEES IN CHINA FROM 2010 TO 2016
Ying L1, Yong M2, Yunyun F3, Chunyan Z1, Zhao L2
1Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2China Health Insurance Research Association, Beijing, China, 3School of Management,Beijing University of Chinese Medicine, Beijing, China

PCN222
G3
POTENTIAL BUDGET IMPACT OF HIGH-COST THERAPIES WITH POTENTIAL FOR EXPANDED INDICATIONS
Kumar VM, Chapman RH, Ollendorf DA
Institute for Clinical and Economic Review, Boston, MA, USA

PCN223
G4
EFFECT OF AGE ON LIVER CANCER INPATIENTS COSTS WITH BASIC MEDICAL INSURANCE SCHEME FOR EMPLOYEES IN CHINA
Ying L1, Yong M2, Jinghu L2, Zhao L2, Jie Z2
1Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2China Health Insurance Research Association, Beijing, China

PCN224
G5
CANCER DRUG RECOMMENDATIONS WITHOUT STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW
Whitney S, Grima A, Samjoo I, Grima D
Cornerstone Research Group, Burlington, ON, Canada

PCN225
G6
TIME TO REIMBURSEMENT FOR ONCOLOGY DRUGS IN EU5
Prada M1, Berard I2, Walzer S3, Darba J4, Greenwood B5
1Intexo, Roma, Italy, 2NEXTEP, PARIS, France, 3MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 4Universitat de Barcelona, Barcelona, Spain, 5Decideum, London, W8 7JB, UK

PCN226
G7
POSITIVE CANCER DRUG RECOMMENDATIONS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW ARE NOT WITHOUT CONDITIONS PLACED ON COST-EFFECTIVENESS
Grima A, Whitney S, Samjoo I, Grima D
Cornerstone Research Group, Burlington, ON, Canada

PCN227
G8
DOES THE TRADITIONAL HTA PROCESS APPROPRIATELY EVALUATE BRAND+BRAND ONCOLOGY COMBINATION DRUGS?
Adler B1, Versoza L1, Jaksa A1, Jao R1, Patel H2, Lemay J2
1Context Matters/DRG, New York, NY, USA, 2Amgen, Thousand Oaks, CA, USA

PCN228
G9
A CRITICAL ASSESSMENT OF THE ROLE OF HEALTH OUTCOMES LIAISONS: TODAY AND THE FUTURE
Wamble D, Brogan AP
RTI Health Solutions, Durham, NC, USA

PCN229
G10
USE OF REAL-WORLD EVIDENCE IN CLINICAL DECISION MAKING BY COMMUNITY ONCOLOGISTS
Kish J, Feinberg B, Hua D, Tchafa A, Smith Y, Klink A, Nabhan C
Cardinal Health Specialty Solutions, Dublin, OH, USA

PCN230
G11
MOLECULAR GUT MICROBIAL CONFIGURATION ANALYSIS BETWEEN THYROID CANCER PATIENTS AND HEALTHY VOLUNTEERS
Ishaq HM1, Mohammad IS2, Shezad M1, Abbas M2, Xu J1, Naveed M2
1Xi’an Jiaotong University, Xian, China, 2China Pharmaceutical University, School of Pharmacy, Nanjing, China

PCN231
G12
COLORECTAL CANCER SCREENING PILOT PROGRAM RESULTS IN HUNGARY
Horváthné Kívés Z, Vajda R, Endrei D, Boncz I
University of Pécs, Pécs, Hungary

PCN232
G13
PREDICTING BREAST CANCER USING ARTIFICIAL NEURAL NETWORK AND LOGISTIC REGRESSION
Xu J
NA, Garnet Valley, PA, USA

PCN233
G14
TREATMENT UTILIZATION PATTERNS AMONG ELDERLY PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA IN THE UNITED STATES BETWEEN 2000 AND 2013
Nagarajan M1, Albarmawi H1, Onukwugha E1, Gandhi AB1, Valderrama A2, Keating K3, Appukkuttan S4, Babajanyan S3, Gharibo M3, Yared JA5
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bayer US (Affiliation at the time that the study was conducted), Whippany, NJ, USA, 3Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA, 4Bayer US, Whippany, NJ, USA, 5University of Maryland, Greenebaum Cancer Center, Baltimore, MD, USA

PCN234
G15
2018 UPDATE OF HEALTH TECHNOLOGY ASSESSMENT DECISIONS ACROSS THE GLOBE: A FOCUS ON ONCOLOGY
Clark RS1, Gittings K2, Campbell C3, Meyer K3
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, L.L.C., Palm Harbor, FL, USA, 3Xcenda, Palm Harbor, FL, USA

PCN235
G16
NICE’S PERSPECTIVE ON THE NEW CANCER DRUGS FUND AND MANAGED ACCESS IN ENGLAND
Edwards HK, Landells LJ, Boysen M
National Institute for Health and Care Excellence, Manchester, UK

PCN236
G17
EX-POST EVALUATION OF RISK-SHARING AGREEMENTS; EVIDENCE FROM SCHEMES IMPLEMENTED FOR ONCOLOGY DRUGS IN SIX COUNTRIES.
Efthymiadou O
London School of Economics and Political Science, London, UK

PCN237
G18
RISK-SHARING AGREEMENT: A MODEL FOR HER2 (+) BREAST CANCER SUITABLE FOR THE CHILEAN CONTEXT.
Paredes Fernandez D1, Lenz Alcayaga R2
1Universidad de Chile, Santiago, Chile, 2Escuela de Salud Pública, Santiago, Chile

PCN238
G19
TREATMENT PATTERNS OF ALK+ NON-SMALL CELL LUNG CANCER PATIENTS IN THE UNITED STATES AND WESTERN EUROPE
Shah-Manek B1, Karki C2, Whitmire SM3, Ilacqua J4, Wriede V5
1Ipsos Healthcare, San Francisco, CA, USA, 2Ipsos Healthcare, New York, NY, USA, 3Ipsos Healthcare, Huntersville, NC, USA, 4Ipsos Healthcare, Mahwah, NJ, USA, 5Ipsos Healthcare, Boston, MA, USA

PCN239
G20
CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE RESOURCE UTILIZATION IN UNRESECTABLE, LOCALLY ADVANCED, STAGE III NON-SMALL CELL LUNG CANCER: A MEDICAL RECORD REVIEW STUDY IN THE UNITED STATES AND CANADA
Kurosky S1, Klein AB2, Parikh RC1, Trantham L1, Zhang Y2, Levine CA1, Kaye JA3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3RTI Health Solutions, Waltham, MA, USA

PCN240
G21
COMPARISON OF SCREENING ALGORITHMS FROM DIFFERENT GUIDELINES FOR THE MANAGEMENT OF HEPATOCELLULAR CARCINOMA
Chawla AS
TheraInsight Pvt. Ltd., Bangalore, India

PCN241
G22
REAL-WORLD TREATMENT PATTERNS FOR PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) TREATED WITH IMMUNO-ONCOLOGY (IO) THERAPY
Huang H1, Shenolikar R2, Seal B2, Tse J1, Burudpakdee C3
1IQVIA, Cambridge, MA, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3IQVIA, Fairfax, VA, USA

PCN242
G23
UNRESECTABLE, LOCALLY ADVANCED, STAGE III NON-SMALL CELL LUNG CANCER: REAL-WORLD CLINICAL CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH CARE RESOURCE UTILIZATION IN EUROPE
Trantham L1, Klein AB2, Parikh RC1, Kurosky S1, Zhang Y2, Levine CA1, Kaye JA3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3RTI Health Solutions, Waltham, MA, USA

PCN243
G24
PATIENT CHARACTERISTICS AND TREATMENT PATTERNS FROM SPEAR-BLADDER: STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER
Doshi G1, Bhanegaonkar A2, Bharmal M3, Phatak H2, Boyd M1, Aguilar KM1, Kim R4, Cislo P4, Kearney M3
1US Oncology Network, McKesson Specialty Health, Houston, TX, USA, 2EMD Serono, Rockland, MA, USA, 3Merck KGaA, Darmstadt, Germany, 4Pfizer, Inc, New York, NY, USA

PCN244
H1
SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Barrows SM1, Wright K1, Copley-Merriman C1, Kaye JA2, Chioda MD3, Wiltshire R4, Torgersen KM5, Masters ET3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Waltham, MA, USA, 3Pfizer Inc., New York, NY, USA, 4Pfizer Limited, Walton Oaks, UK, 5Pfizer, Inc., Oslo, Norway

PCN245
H2
PROGRAMMED CELL DEATH LIGAND-1 TESTING AMONG PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER: A MULTINATIONAL MEDICAL RECORD REVIEW STUDY
Parikh RC1, Klein AB2, Kurosky S1, Trantham L1, Zhang Y2, Levine CA1, Kaye JA3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2AstraZeneca, Gaithersburg, MD, USA, 3RTI Health Solutions, Waltham, MA, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.